Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INO-3401 · 1 trial · 1 indication
Frequency and severity of local and systemic reactogenicity, signs and symptoms, adverse events and serious adverse events.
| Arm | Type | Description |
|---|---|---|
| All subjects | EXPERIMENTAL | All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3. |
| Name | Type | Description |
|---|---|---|
| INO-3401 + EP | BIOLOGICAL | All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3. |
Inclusion Criteria: * Written informed consent in accordance with institutional guidelines. If required by local law, candidates must also authorize the release and use of protected health information (PHI); * Enrollment in and received at least one vaccination in study FLU-001; * Adults of either ...
INO-3401 is an investigational monoclonal antibody developed by Inovio Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial involving healthy adult volunteers. The specific disease indication for INO-3401 has not been publicly disclosed, and the compound remains in early-stage clinical development.
INO-3401 is developed by Inovio Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol INO. Inovio is the sponsor of the clinical program evaluating INO-3401, a monoclonal antibody candidate that has completed one Phase 1 study in healthy volunteers.
INO-3401 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The study enrolled 22 healthy adult volunteers in the United States. INO-3401 is investigational and has not been approved by the FDA for any indication.
INO-3401 has been evaluated in one completed Phase 1 trial, NCT01403155, titled a follow-on study with an H5 influenza vaccine for subjects who participated in study FLU-001. The trial enrolled 22 healthy volunteers aged 18 years and older in the United States and was an uncontrolled study.